H2 Receptor Antagonists (H2 Blockers):

H2 receptor antagonists ("H2 blockers") are a core acid-suppressing drug class tested on the NCLEX. This guide reviews the agents in the class, how they work, when they are used, and the safety, monitoring, and interaction issues nurses must recognize — especially the unique problems with cimetidine and the renal/CNS risks in older adults.

Drugs in the Class

Memory cue: H2 blockers end in -tidine.

Famotidine (Pepcid) — Most commonly used H2 blocker; fewer drug interactions; available IV and PO.
Cimetidine (Tagamet) — First H2 blocker; inhibits CYP450 enzymes (many interactions); causes anti-androgen effects.
Nizatidine (Axid) — Similar efficacy to other H2 blockers; primarily renally excreted.
Ranitidine (Zantac) — Withdrawn from the US market due to NDMA carcinogen contamination; no longer available.

Mechanism of Action

Competitively and reversibly block histamine H2 receptors on gastric parietal cells.
Prevent histamine-stimulated gastric acid production.
Reduce both basal and stimulated acid secretion by ~70%.
Particularly effective at suppressing nocturnal acid secretion — important for peptic ulcer healing.
Less potent than PPIs because they do not block the gastrin or acetylcholine pathways.

Indications

Short-term treatment of active duodenal and gastric ulcers (FDA-approved).
GERD — symptomatic relief and treatment of erosive esophagitis (lower efficacy than PPIs).
Hypersecretory conditions such as Zollinger-Ellison syndrome.
OTC use for prevention/relief of infrequent heartburn or acid indigestion.
Off-label: stress ulcer prophylaxis in critically ill patients; persistent nocturnal symptoms in patients already on PPIs.

Side Effects

Common: headache, dizziness, drowsiness, fatigue, mild GI upset.
CNS effects — confusion, hallucinations, delirium — significant risk in elderly and critically ill patients.
Cimetidine-specific anti-androgen effects: gynecomastia, impotence, decreased libido.
Vitamin B12 deficiency with long-term use (reduced acid impairs B12 release from food proteins).
Rare hepatotoxicity reported with cimetidine and (now-withdrawn) ranitidine.

Labs, Monitoring & Renal Adjustments

Monitor for GI bleeding — including occult blood in stool.
Monitor renal function (BUN, creatinine) — all H2 blockers are renally excreted.
Periodic vitamin B12 levels in long-term therapy.
Monitor INR closely when cimetidine is combined with warfarin.
Dose adjustment is mandatory when CrCl falls below 60 mL/min or 30 mL/min.

Drug Interactions

Cimetidine inhibits multiple CYP450 enzymes (1A2, 2C9, 2D6) — main source of interactions in the class.
Cimetidine can raise levels of warfarin, phenytoin, and theophylline to toxic ranges.
Cimetidine + dofetilide is contraindicated — risk of torsades de pointes.
H2 blockers reduce absorption of ketoconazole — separate doses by at least 2 hours.
Famotidine and nizatidine do not inhibit CYP450 — safer in polypharmacy.

Administration & Nursing Considerations

Give once-daily doses at bedtime to maximize nocturnal acid suppression.
Onset: ~60 minutes; duration: 4–10 hours.
Administer IV famotidine slowly in hospitalized patients who cannot tolerate PO.
Teach patients that OTC H2 blockers should not be used > 14 consecutive days.
Generally considered safe in pregnancy; pass into breast milk, so breastfeeding is not recommended during therapy.

H2 Blockers vs. PPIs

Feature	H2 Blockers	PPIs
Mechanism	Block histamine H2 receptors	Irreversibly block proton pump
Acid suppression	~70% reduction	~99% reduction
Onset	~60 minutes	1–4 days
Duration	4–10 hours	24+ hours
Meal timing	With or without food	30–60 minutes before meals
Tolerance	Develops with long-term use	No tolerance develops
Erosive esophagitis	Lower efficacy	Superior; first-line

Common NCLEX Traps

Forgetting cimetidine causes CYP450 inhibition while famotidine does not.
Missing cimetidine's anti-androgen effects (gynecomastia, impotence).
Giving H2 blockers to elderly patients without monitoring for confusion/CNS effects.
Using H2 blockers as first-line for erosive esophagitis when PPIs are superior.
Failing to adjust doses for renal impairment.
Forgetting that ranitidine is no longer available due to NDMA.
Overlooking B12 deficiency with long-term use.
Confusing H2 blocker mechanism with PPI mechanism.
Giving the dose at the wrong time of day — nocturnal/bedtime dosing is most effective.
Not recognizing famotidine as the safest choice in polypharmacy.

Key Takeaways

All H2 blockers end in -tidine and reduce gastric acid by ~70% by blocking histamine H2 receptors on parietal cells.
Cimetidine is the high-yield exam drug: CYP450 inhibition, anti-androgen effects, and contraindicated with dofetilide.
Famotidine is the safest choice in polypharmacy and is available IV and PO.
Dose at bedtime for nocturnal acid suppression; adjust for renal impairment.
Monitor elderly patients for CNS effects (confusion, delirium) and long-term users for vitamin B12 deficiency.
PPIs outperform H2 blockers for erosive esophagitis; ranitidine is off the market due to NDMA contamination.

H2 Receptor Antagonists (H2 Blockers): Nursing Pharmacology Study Guide